Anthem Biosciences Limited
Founded in 2006, Anthem Biosciences Ltd provides integrated CRDMO services and specializes in manufacturing specialty ingredients, focusing on both New Chemical Entities and New Biological Entities, with platforms like RNA interference and Antibody-Drug Conjugates.
What Anthem files
- Others29
- Investor Meet18
- Updates11
- Important6
- PPTs5
- Board Meeting4
Anthem Biosciences' Q1FY27 revenue dropped 22.6% YoY to ₹418.2 Cr, with profit after tax falling 11.7% to ₹119.9 Cr. Both CRDMO and Specialty Ingredients segments saw revenue declines. Despite this, the company maintained strong margins, with EBITDA at 39.6% and PAT at 27.1%, showing YoY improvement due to cost discipline....
Anthem Biosciences reported Q1FY27 consolidated revenue of ₹418.2 Cr, down 22.6% YoY. Profit After Tax (PAT) also saw a dip of 11.7% YoY to ₹119.9 Cr. The CRDMO segment contributed ₹340.8 Cr (81.5% of revenue) and Specialty Ingredients ₹77.4 Cr. Despite lower top-line, the company maintained strong margins, with EBITDA...
Anthem Biosciences delivered a stellar Q4FY26, marking its highest-ever revenue quarter! Full-year FY26 revenue grew 15% YoY to ₹2,124.3 Cr, with Q4 alone soaring 26% YoY to ₹610.9 Cr. Profitability surged, with FY26 EBITDA up 30.8% to ₹989.6 Cr (43.4% margin) and PAT up 31.1% to ₹591.8 Cr (26.0% margin)....
Here's a concise summary of Anthem Biosciences' Q3FY26 and 9MFY26 performance: **1. Business Performance:** Anthem Biosciences' Q3FY26 revenue dipped 15% YoY to ₹423.2 Cr, impacted by a higher base. However, 9MFY26 revenue still grew 11.2% YoY to ₹1513.4 Cr. While Q3 CRDMO revenue was down 19.4% YoY, Specialty Ingredients saw...
Here is the summary: **Financial Highlights:** Anthem Biosciences reported strong Q1FY26 results: Revenue up 59.5% YoY to ₹540.2 Cr, led by CRDMO (₹452.7 Cr, up 70.5%). EBITDA grew 52.7% to ₹214.3 Cr (38.1% margin). PAT jumped 64.8% to ₹135.8 Cr (24.1% margin). Net cash: ₹784.8 Cr. **Strategic Initiatives & Growth...